Improvement of Quality of Life in Tumor Patients after an ImmunomodulatoryTreatment with Standardized Mistletoe Lectin and Arabinoxylan Plant Extracts

Background: In the last decades a special attention has been focused on the role of disturbed immune balance in the behavioral co-morbidities of tumor patients. The prognostic significance of malignant tumor-induced imbalance in the innate immune system is well known. The innate system uses a limited number of Pattern Recognition Receptors (PRR) to recognize conserved Pathogenic Associated Molecular Pattern (PAMP) structures expressed by microbes but not by host. Growing experiences suggest that the improvement of tumor induced disturbance of immune balance by using standardized plant PAMP like preparations goes often together with a better quality of life (QoL). Methods: In this study tumor patients were treated with standardized plant immunomodulators (mistletoe lectin and arabinoxylan) which were shown to activate the type-1 natural immune cells against cancer. After at least a therapy for six months the patients were asked about their QoL using questionnaires. Results: The following answers were received from the 35 patients: Decrease of pains: 17%, improvement of anxiety: 40%, Increase of physical activity: 71%, Improvement of appetite: 66%, Improvement of sleep: 40%, improvement of digestion: 43%, decrease of side effects during oncotherapy: 71%, beneficial judgement of the progress of disease based on clinical findings: 46%. As shown, the most important effects were the improvement of physical activity and decrease of side effects during conventional oncotherapy. Conclusion: Present results may support the relationship between tumor induced disturbance of immune balance and the tumor induced behavioral co-morbidities. Further clinical investigations are necessary to proof this hypothesis.

[1]  P. Perjési,et al.  Can a synergistic activation of pattern recognition receptors by plant immunomodulators enhance the effect of oncologic therapy? Case Report of a patient with uterus and ovary , 2015 .

[2]  A. Kirsch,et al.  Case Reports of Cancer Patients with Hepatic Metastases Treated by Standardized Plant Immunomodulatory Preparations , 2013 .

[3]  A. Kirsch,et al.  Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy. , 2011, Journal of alternative and complementary medicine.

[4]  P. Perjési,et al.  Difficulties and Perspectives of Immunomodulatory Therapy with Mistletoe Lectins and Standardized Mistletoe Extracts in Evidence-Based Medicine , 2011, Evidence-based complementary and alternative medicine : eCAM.

[5]  A. Dalgleish,et al.  How immunotherapy can enhance the response to other modalities and improve outcome and quality of life. , 2009, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[6]  S. Ancoli-Israel,et al.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Reiche,et al.  Stress and depression-induced immune dysfunction: Implications for the development and progression of cancer , 2005, International review of psychiatry.

[8]  M. Matsuura,et al.  Augmentation of Macrophage Phagocytosis by Modified Arabinoxylan Rice Bran (MGN-3/Biobran) , 2004, International journal of immunopathology and pharmacology.

[9]  J. Peter-Katalinic,et al.  Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. , 2004, Biochemistry.

[10]  D. Theobald Cancer pain, fatigue, distress, and insomnia in cancer patients. , 2004, Clinical cornerstone.

[11]  R. Saller,et al.  Effect of a Recombinant Lectin, Viscum album Agglutinin on the Secretion of Interleukin-12 in Cultured Human Peripheral Blood Mononuclear Cells and on NK-Cell-Mediated Cytotoxicity of Rat Splenocytes in vitro and in vivo , 1998, Natural Immunity.

[12]  J. Beuth,et al.  Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. , 1998, Anticancer research.

[13]  J. Beuth,et al.  Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. , 1994, Anticancer research.

[14]  S. Straus Defining the chronic fatigue syndrome. , 1992, Archives of internal medicine.

[15]  K. Frei,et al.  Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. , 1990, Cancer research.

[16]  H. Gabius,et al.  Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. , 1989, Cancer research.